GURUFOCUS.COM » STOCK LIST » USA » NAS » OncoCyte Corp (NAS:OCX) » Definitions » Inventory-to-Revenue
Switch to:

OncoCyte (NAS:OCX) Inventory-to-Revenue

: 0.00 (As of Sep. 2022)
View and export this data going back to 2015. Start your Free Trial

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. OncoCyte's Average Total Inventories for the quarter that ended in Sep. 2022 was $0.00 Mil. OncoCyte's Revenue for the three months ended in Sep. 2022 was $1.02 Mil. OncoCyte's Inventory-to-Revenue for the quarter that ended in Sep. 2022 was 0.00.

OncoCyte's Inventory-to-Revenue for the quarter that ended in Sep. 2022 stayed the same from Jun. 2022 (0.00) to Jun. 2022 (0.00)

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. OncoCyte's Days Inventory for the three months ended in Sep. 2022 was 0.00.

Inventory Turnover measures how fast the company turns over its inventory within a year.


OncoCyte Inventory-to-Revenue Historical Data

The historical data trend for OncoCyte's Inventory-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

OncoCyte Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Inventory-to-Revenue
Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - 0.04

OncoCyte Quarterly Data
Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
Inventory-to-Revenue Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 0.09 0.21 - -

Competitive Comparison

For the Biotechnology subindustry, OncoCyte's Inventory-to-Revenue, along with its competitors' market caps and Inventory-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

   

OncoCyte Inventory-to-Revenue Distribution

For the Biotechnology industry and Healthcare sector, OncoCyte's Inventory-to-Revenue distribution charts can be found below:

* The bar in red indicates where OncoCyte's Inventory-to-Revenue falls in comparison to its industry or sector. The grey bar indicates the Inventory-to-Revenue's extreme value range as defined by GuruFocus.



OncoCyte Inventory-to-Revenue Calculation

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

OncoCyte's Inventory-to-Revenue for the fiscal year that ended in Dec. 2021 is calculated as

Inventory-to-Revenue (A: Dec. 2021 )
=Average Total Inventories / Revenue
=( (Total Inventories (A: Dec. 2020 ) + Total Inventories (A: Dec. 2021 )) / count ) / Revenue (A: Dec. 2021 )
=( (0 + 0.304) / 1 ) / 7.727
=0.304 / 7.727
=0.04

OncoCyte's Inventory-to-Revenue for the quarter that ended in Sep. 2022 is calculated as

Inventory-to-Revenue (Q: Sep. 2022 )
=Average Total Inventories / Revenue
=( (Total Inventories (Q: Jun. 2022 ) + Total Inventories (Q: Sep. 2022 )) / count ) / Revenue (Q: Sep. 2022 )
=( (0 + 0) / 1 ) / 1.017
=0 / 1.017
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


OncoCyte  (NAS:OCX) Inventory-to-Revenue Explanation

An increase in Inventory-to-Revenue from one quarter to the next indicates that one of the following is happening:

1. investment in inventory is growing more rapidly than revenue
2. revenue are dropping
No matter which situation is causing the problem, an increase in the Inventory-to-Revenue may signal an oncoming cash flow problem.

Likewise, a decrease in the Inventory-to-Revenue from one quarter to next indicates that one of these is occurring:

1. investment in inventory is shrinking in relation to revenue
2. revenue are increasing
No matter which situation is causing the reduction in the Inventory-to-Revenue, either one suggests that business's inventory levels and its cash flow are effectively managed.

More Related Terms:

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

OncoCyte's Days Inventory for the three months ended in Sep. 2022 is calculated as:

Days Inventory=Average Total Inventories (Q: Sep. 2022 )/Cost of Goods Sold (Q: Sep. 2022 )*Days in Period
=0/2.191*365 / 4
=0.00

2. Inventory Turnover measures how fast the company turns over its inventory within a year.

OncoCyte's Inventory Turnover for the quarter that ended in Sep. 2022 is calculated as

Inventory Turnover=Cost of Goods Sold (Q: Sep. 2022 ) / Average Total Inventories (Q: Sep. 2022 )
=2.191 / 0
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


OncoCyte Inventory-to-Revenue Related Terms

Thank you for viewing the detailed overview of OncoCyte's Inventory-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


OncoCyte (NAS:OCX) Business Description

OncoCyte logo
Traded in Other Exchanges
Address
15 Cushing, Irvine, CA, USA, 92618
OncoCyte Corp focuses on the discovery, development, and commercialization of novel, non-invasive, liquid biopsy diagnostics for the early detection of cancer. The company develops diagnostic tests based on liquid biopsies using blood or urine samples for detecting lung, bladder, and breast cancers. In addition, it also develops screening diagnostics as potential replacements for screening imaging procedures that do not meet the needs of patients, health care providers or payers. Geographically operation of the group is carried through the United States, and it earns revenue from the sale of diagnostic tests.
Executives
Josh Riggs officer: Interim CEO 15 CUSHING, IRVINE CA 92618
Lou Silverman director
James Yang Liu officer: Controller, PAO C/O ONCOCYTE CORPORATION, 15 CUSHING, IRVINE CA 92618
John Peter Gutfreund director C/O ONCOCYTE CORPORATION, 15 CUSHING, IRVINE CA 92618
Anish M. John officer: SVP, Finance, and Interim CFO C/O ONCOCYTE CORPORATION,, 15 CUSHING, IRVINE CA 92618
Pura Vida Investments, Llc 10 percent owner 512 W 22ND STREET, 7TH FLOOR, NEW YORK NY 10011
Efrem Kamen 10 percent owner C/O PURA VIDA INVESTMENTS, LLC, 512 W 22ND STREET, 7TH FLOOR, NEW YORK NY 10011
Gisela Paulsen officer: Chief Operating Officer 5505 ENDEAVOR LANE, MADISON WI 53719
Li Yu officer: VP Cntrllr/Prncpl Acctng Offcr 120 NEWPORT CENTER DRIVE., NEWPORT BEACH CA 92660
Jennifer L. Carter director C/O DFP SPONSOR LLC, 780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017
Douglas T. Ross officer: Chief Medical Officer 15 CUSHING, IRVINE CA 92618
Tony T Kalajian officer: SVP-Chief Accounting Officer 1010 ATLANTIC AVENUE, SUITE 102, ALAMEDA CA 94501
Melinda Griffith director 1010 ATLANTIC AVENUE, SUITE 102, ALAMEDA CA 94501
Padma Sundar officer: SVP, Marketing & Market Access 1010 ATLANTIC AVENUE, SUITE 102, ALAMEDA CA 94501
Ronald Asbury Andrews director 5791 VAN ALLEN WAY, CARLSBAD CA 92008

OncoCyte (NAS:OCX) Headlines

Other Sources